206 related articles for article (PubMed ID: 25592320)
1. The many different faces of major depression: it is time for personalized medicine.
Korte SM; Prins J; Krajnc AM; Hendriksen H; Oosting RS; Westphal KG; Korte-Bouws GA; Olivier B
Eur J Pharmacol; 2015 Apr; 753():88-104. PubMed ID: 25592320
[TBL] [Abstract][Full Text] [Related]
2. Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited.
Prins J; Olivier B; Korte SM
Expert Opin Investig Drugs; 2011 Aug; 20(8):1107-30. PubMed ID: 21682663
[TBL] [Abstract][Full Text] [Related]
3. The potential and limitations of DOV 216,303 as a triple reuptake inhibitor for the treatment of major depression: a microdialysis study in olfactory bulbectomized rats.
Prins J; Westphal KG; Korte-Bouws GA; Quinton MS; Schreiber R; Olivier B; Korte SM
Pharmacol Biochem Behav; 2011 Jan; 97(3):444-52. PubMed ID: 20934452
[TBL] [Abstract][Full Text] [Related]
4. The triple reuptake inhibitor DOV 216,303 induces long-lasting enhancement of brain reward activity as measured by intracranial self-stimulation in rats.
Prins J; Kenny PJ; Doomernik I; Schreiber R; Olivier B; Mechiel Korte S
Eur J Pharmacol; 2012 Oct; 693(1-3):51-6. PubMed ID: 23010469
[TBL] [Abstract][Full Text] [Related]
5. Monoamine neurocircuitry in depression and strategies for new treatments.
Hamon M; Blier P
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():54-63. PubMed ID: 23602950
[TBL] [Abstract][Full Text] [Related]
6. Triple uptake inhibitors: therapeutic potential in depression and beyond.
Chen Z; Skolnick P
Expert Opin Investig Drugs; 2007 Sep; 16(9):1365-77. PubMed ID: 17714023
[TBL] [Abstract][Full Text] [Related]
7. Effects of serotonin-norepinephrine reuptake inhibitors on locomotion and prefrontal monoamine release in spontaneously hypertensive rats.
Umehara M; Ago Y; Fujita K; Hiramatsu N; Takuma K; Matsuda T
Eur J Pharmacol; 2013 Feb; 702(1-3):250-7. PubMed ID: 23376565
[TBL] [Abstract][Full Text] [Related]
8. Faster, better, stronger: towards new antidepressant therapeutic strategies.
O'Leary OF; Dinan TG; Cryan JF
Eur J Pharmacol; 2015 Apr; 753():32-50. PubMed ID: 25092200
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological differences of serotonin reuptake inhibitors and possible clinical relevance.
Leonard BE
Drugs; 1992; 43 Suppl 2():3-9; discussion 9-10. PubMed ID: 1378371
[TBL] [Abstract][Full Text] [Related]
10. Application of antidepressants in depression: A systematic review and meta-analysis.
Yuan Z; Chen Z; Xue M; Zhang J; Leng L
J Clin Neurosci; 2020 Oct; 80():169-181. PubMed ID: 33099342
[TBL] [Abstract][Full Text] [Related]
11. The putative antidepressant DOV 216,303, a triple reuptake inhibitor, increases monoamine release in the prefrontal cortex of olfactory bulbectomized rats.
Prins J; Denys DA; Westphal KG; Korte-Bouws GA; Quinton MS; Schreiber R; Groenink L; Olivier B; Korte SM
Eur J Pharmacol; 2010 May; 633(1-3):55-61. PubMed ID: 20153745
[TBL] [Abstract][Full Text] [Related]
12. [Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram].
Favré P
Encephale; 2012 Feb; 38(1):86-96. PubMed ID: 22381728
[TBL] [Abstract][Full Text] [Related]
13. [Comparative efficacy and acceptability of new-generation antidepressants. Synthesis meta-analysis Cipriani].
Gaillard R
Encephale; 2009 Oct; 35(5):499-504. PubMed ID: 19853726
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis.
Cipriani A; Furukawa TA; Salanti G; Geddes JR; Higgins JP; Churchill R; Watanabe N; Nakagawa A; Omori IM; McGuire H; Tansella M; Barbui C
Lancet; 2009 Feb; 373(9665):746-58. PubMed ID: 19185342
[TBL] [Abstract][Full Text] [Related]
15. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure.
Nutt D; Demyttenaere K; Janka Z; Aarre T; Bourin M; Canonico PL; Carrasco JL; Stahl S
J Psychopharmacol; 2007 Jul; 21(5):461-71. PubMed ID: 17050654
[TBL] [Abstract][Full Text] [Related]
16. Effects of monoamine reuptake inhibitors in assays of acute pain-stimulated and pain-depressed behavior in rats.
Rosenberg MB; Carroll FI; Negus SS
J Pain; 2013 Mar; 14(3):246-59. PubMed ID: 23332494
[TBL] [Abstract][Full Text] [Related]
17. Antidepressant-like effects of novel triple reuptake inhibitors, PRC025 and PRC050.
Shaw AM; Boules M; Zhang Y; Williams K; Robinson J; Carlier PR; Richelson E
Eur J Pharmacol; 2007 Jan; 555(1):30-6. PubMed ID: 17109850
[TBL] [Abstract][Full Text] [Related]
18. Differential period of onset of action of fluvoxamine, paroxetine and milnacipran for depression.
Morishita S; Arita S
Hum Psychopharmacol; 2003 Aug; 18(6):479-82. PubMed ID: 12923828
[TBL] [Abstract][Full Text] [Related]
19. Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor.
Skolnick P; Krieter P; Tizzano J; Basile A; Popik P; Czobor P; Lippa A
CNS Drug Rev; 2006; 12(2):123-34. PubMed ID: 16958986
[TBL] [Abstract][Full Text] [Related]
20. Depression and antidepressants: insights from knockout of dopamine, serotonin or noradrenaline re-uptake transporters.
Haenisch B; Bönisch H
Pharmacol Ther; 2011 Mar; 129(3):352-68. PubMed ID: 21147164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
